NASDAQ:CRBP - Corbus Pharmaceuticals Holdings, Inc.
$7.04
 $0.11
+1.59%
4:00PM EDT
2019-04-18
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CRBP     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 65   199. 07   233. 87  
42 stocks rank:  3. 70 K 1. 43 K 1. 06 K
# analyst opinions:  8. 00   14. 48   14. 09  
mean recommendation:  1. 80   2. 09   2. 01  

quick ratio:  2. 31   5. 29   1. 92  
current ratio:  2. 45   5. 64   2. 40  

target price low:  7. 64   84. 50   115. 74  
target price avg:  12. 00   110. 73   137. 39  
target price high:  12. 10   136. 41   157. 80  
1-yr high:  8. 95   114. 11   138. 85  
last close:  7. 04   87. 56   116. 78  
50-day avg:  7. 24   95. 43   123. 53  
200-day avg:  6. 51   94. 13   121. 20  
1-yr low:  4. 65   72. 67   98. 41  
volume:  886. 43 K 2. 43 M 4. 85 M
50-day avg volume:  1. 84 M 2. 72 M 4. 97 M
200-day avg volume:  1. 21 M 2. 90 M 4. 58 M

1-day return:  1. 59 % -0. 40 % 0. 07 %
this week return:  0. 86 % -5. 72 % -4. 11 %
12-wk return:  0. 14 % 1. 78 % -0. 04 %
52-wk return:  6. 97 % 10. 81 % 14. 09 %

enterprise value (EV):  408. 12 M 51. 19 B 117. 96 B
market cap:  453. 38 M 43. 00 B 104. 52 B
EBITDA:  -56. 25 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -7. 25   4. 34   13. 27  
enterprise/revenue (EV/R):  84. 63   68. 16   13. 68  
total revenue:  4. 82 M 10. 61 B 38. 24 B
total debt:  394. 31 K 12. 22 B 16. 66 B
debt/equity:  1. 43   46. 86   89. 46  
net income (common):  -55. 67 M 2. 20 B 4. 21 B

shares outstanding:  64. 40 M 570. 91 M 1. 24 B
shares:  55. 89 M 571. 02 M 1. 23 B
shares short:  16. 13 M 9. 93 M 16. 79 M
shares short prior month:  12. 97 M 9. 96 M 16. 58 M
short ratio:  6. 88   5. 31   3. 30  
short % of float:  30. 07 % 5. 81 % 2. 61 %
total cash/share:  0. 65   11. 13   9. 30  
total cash:  41. 75 M 6. 70 B 7. 10 B
free cash flow:  -19. 37 M 3. 58 B 4. 74 B
operating cash flow:  -30. 07 M 4. 14 B 6. 32 B

book value:  0. 48   12. 76   26. 84  
price/book:  14. 64   3. 08   -1. 74  
operating margins:  -1176. 78 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  53. 62 % --- ---
1-yr mean volatility:  0. 14 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 98   2. 39   4. 08  
forward EPS:  -1. 45   3. 97   7. 14  
P/E:  -7. 21   13. 59   22. 83  
forward P/E:  -4. 81   -20. 05   14. 49  
PE/G:  0. 67   -1. 46   1. 68  
growth:  -10. 75 % 126. 81 % 29. 29 %
earnings high:  -0. 24   1. 02   1. 63  
earnings avg:  -0. 27   0. 76   1. 51  
earnings low:  -0. 31   0. 47   1. 39  
revenue high:  2. 00 M 2. 68 B 10. 71 B
revenue avg:  1. 53 M 2. 59 B 10. 49 B
revenue low:  950. 00 K 2. 49 B 10. 25 B
return on assets:  -62. 24 % -2. 80 % 5. 29 %
return on equity:  -130. 52 % -18. 52 % 7. 38 %
revenue/share:  0. 09   13. 27   55. 24  

beta (1yr vs S&P500):  1. 48   1. 24   0. 93  
sharpe (1yr):  0. 42   0. 29   0. 60  

held % insiders:  5. 45 % 6. 38 % 3. 38 %
held % institutions:  44. 44 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CRBP
.    + 1.676 =         1.676 :: INITIAL WEIGHT
.   + 46.403 =         48.08 :: spline projection addition
.    x 1.432 =        68.851 :: industry recommendation factor
.    x 2.515 =       173.178 :: symbol recommendation factor
.    x 1.758 =       304.514 :: EV/R factor
.    x 0.994 =       302.619 :: return on assets factor
.    x 0.987 =       298.669 :: return on equity factor
.    x 2.434 =       726.902 :: current ratio factor
.    x 1.328 =       965.583 :: quick ratio factor
.     x 1.07 =      1033.376 :: short ratio factor
.    x 2.286 =      2361.797 :: price-to-book factor
.    x 1.015 =      2397.637 :: debt-to-equity factor
.    x 1.085 =      2601.366 :: 5-day avg > 200-day avg
.    x 1.112 =      2893.045 :: 50-day avg > 200-day avg
.    x 2.042 =      5908.438 :: P/E weight
.    x 1.105 =      6529.837 :: PE/G factor
.    x 1.413 =      9228.174 :: beta factor
.    x 0.422 =      3890.371 :: sharpe factor
.    x 1.294 =      5032.207 :: target low factor
.     x 1.28 =      6440.172 :: target mean factor
.    x 1.085 =      6985.936 :: target high factor
.    x 1.312 =      9163.091 :: industry 2-weeks return factor
.    x 0.926 =      8488.607 :: "drift" penalty 4 days ago
.    x 0.963 =      8171.686 :: overall "drift" factor
.    x 0.464 =      3789.768 :: largest single-day jump factor
.    x 0.099 =       373.744 :: low price factor
.      x 1.0 =       373.684 :: factor hist industry gain for week 15
.   cubeRoot =         7.203 :: reduced to standardize
.    - 22.94 =         0.647 :: add/subtract for performance
.                      0.647 :: FINAL WEIGHT for NASDAQ:CRBP


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org